Department of Otorhinolaryngology, CHU Saint-Pierre, Rue aux Laines 105, 1000, Brussels, Belgium.
Department of Otorhinolaryngology, epiCURA, Mons, Belgium.
Eur Arch Otorhinolaryngol. 2022 Dec;279(12):5951-5953. doi: 10.1007/s00405-022-07560-y. Epub 2022 Jul 29.
Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD), lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results.
In the present study, we investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD by the Sniffing Stick test (TDI score) and a linker-scale from 0 (none) to 3 (strong) and we compare the result to a control group.
At 1 month post-PRP injection, the mean TDI scores significantly improved by 6.7 points in the PRP group (p < 0,001), the mean self-assessment of improvement in smell function was 1.8 (mild-to-moderate) in the PRP group, which was significantly higher than the score (0.3) in the control group (p < 0,001).
Our results showed that PRP in the olfactory cleft can increase the olfactory threshold 1 month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment, because no adverse effects were reported throughout the study.
NCT05226546.
嗅觉功能障碍(OD)是 2019 年冠状病毒病(COVID-19)的一种已知症状,占患者的 48%至 85%。在 1%至 10%的病例中,患者会出现慢性嗅觉功能障碍(COD),持续时间超过 6 个月。最近,富血小板血浆(PRP)被用于治疗非 COVID-19 COD 的患者,作者报告了令人鼓舞的结果。
在本研究中,我们通过嗅觉测试(TDI 评分)和 0(无)至 3(强)的链接量表,调查了 56 例 COVID-19 COD 患者使用 PRP 注射的有用性和安全性,并将结果与对照组进行比较。
在 PRP 注射后 1 个月,PRP 组的 TDI 评分平均显著提高 6.7 分(p<0.001),PRP 组自我评估的嗅觉功能改善平均为 1.8(轻度至中度),明显高于对照组的评分(0.3)(p<0.001)。
我们的结果表明,PRP 在嗅裂中可以在注射后 1 个月提高嗅觉阈值。此外,我们的结果表明,治疗时机可能是一个重要因素,PRP 是一种安全的治疗方法,因为整个研究过程中没有报告不良反应。
NCT05226546。